Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 12,927 |
|
|||||
| News | - | ||||||
| Day High | 2.129 | Low High |
|||||
| Day Low | 1.9739 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.10 | -4.78% | 1.99 | 16:54:28 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.04 | 1.9739 | 2.129 | 1.99 | 2.09 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 107 | 12,927 | $ 2.01 | $ 25,934 | - | 1.3601 - 4.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:36:27 | 20 | $ 2.07 | USD |
Aeterna Zentaris Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 13.16M | 4.86M | - | 5.64M | -22.73M | -4.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aeterna Zentaris News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.64 | 2.24 | 1.64 | 2.11 | 25,289 | 0.35 | 21.34% |
| 1 Month | 1.45 | 2.24 | 1.3601 | 1.81 | 11,430 | 0.54 | 37.24% |
| 3 Months | 2.63 | 2.74 | 1.3601 | 1.97 | 10,060 | -0.64 | -24.33% |
| 6 Months | 2.78 | 3.21 | 1.3601 | 2.45 | 10,020 | -0.79 | -28.42% |
| 1 Year | 3.63 | 4.00 | 1.3601 | 2.92 | 12,929 | -1.64 | -45.18% |
| 3 Years | 0.42 | 5.90 | 0.1645 | 1.29 | 2,456,218 | 1.57 | 373.81% |
| 5 Years | 3.10 | 5.90 | 0.1645 | 1.18 | 1,874,345 | -1.11 | -35.81% |
Aeterna Zentaris Description
| AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |
